2-(4-chloro-3-nitrophenyl)-2-methylpropanoic acid | 178556-45-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-chloro-3-nitrophenyl)-2-methylpropanoic acid
• 英文别名: 2-(4-chloro-3-nitrophenyl)-2-methylpropionic acid
• CAS: 178556-45-1
• 化学式: C₁₀H₁₀ClNO₄
• 分子量: 243.647
• InChiKey: ACKABRICAWAUFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(4-chloro-3-nitrophenyl)-2-methylpropanoic acid 在 吡啶 、 氯化亚砜 、 20 % Pd(OH)2/C 、 氢气 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 甲醇 、 乙二醇二甲醚 、 二氯甲烷 、 水 、 二甲基亚砜 、 乙酸乙酯 为溶剂， 反应 11.0h， 生成 2-{4-chloro-3-[(2,5-dimethyl-4-{[(2S)-4-methyl-3,4-dihydro-2H-1,4-benzoxazin-2-yl]methoxy}benzoyl)amino]phenyl}-2-methylpropanoic acid
  参考文献：
  名称：

  Discovery of new orally active prostaglandin D2 receptor antagonists

  摘要：

  To identify an orally available drug candidate, a series of 3-benzoylaminophenylacetic acids were synthesized and evaluated as prostaglandin D-2 (PGD(2)) receptor antagonists. Some of the compounds tested were found to exhibit excellent inhibitory activity against cAMP accumulation in human platelet rich plasma (hPRP), which is one of the indexes of DP antagonism. The optimization process including improvement of the physicochemical properties such as solubility, which may result in an improved pharmacokinetic (PK) profile, is presented. Optimized compounds were studied for their pharmacokinetics and in vivo potential. A structure-activity relationship study is also presented. Some of the test compounds were found to have in vivo efficacy towards the inhibition of PGD(2)-induced and OVA-induced vascular permeability in guinea pig conjunctiva. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.08.065
• 作为产物：
  描述：

  methyl 2-(4-chloro-3-nitrophenyl)-2-methylpropanoate 在 盐酸 、 氢氧化钾 作用下， 以 甲醇 、 正己烷 、 水 为溶剂， 生成 2-(4-chloro-3-nitrophenyl)-2-methylpropanoic acid
  参考文献：
  名称：

  Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same

  摘要：

  提供的是以下公式（I）所代表的1,5-苯二氮䓬啉衍生物的钙盐： （其中，R1代表较低的烷基，R2代表苯基或环己基，Y代表单键或较低的烷基烯基）；一种制备这些盐的方法；以及含有它们作为活性成分的药物。 这些化合物表现出对胃酸分泌的强效抑制活性，以及对胃泌素和/或CCK-B受体的强效拮抗作用。

  公开号：

  US20030096809A1

文献信息

• Process for the preparation of nitrobenzene derivatives
  申请人：Rhone-Poulenc Rorer S.A.

  公开号：US05719317A1

  公开（公告）日：1998-02-17

  A method for preparing a compound of formula (I), wherein R.sub.1 and R.sub.2, which are the same or different, are a hydrogen atom or an alkyl or alkoxy radical, or R.sub.1 and R.sub.2, taken together with the carbon atom to which they are attached, form a cycloalkyl radical containing 3-6 carbon atoms. The method comprises dehalogenating a derivative of formula (lI), wherein R.sub.1 and R.sub.2 have the same meanings as in formula (1) and Hal is a chlorine or bromine atom, using 1-2 mol of triethylammonium formate, in the presence of 0.002-0.1 mol of coal-borne palladium per mol of the compound of formula (II), in aceonitrile or tetrahydrofuran and at a temperature between 50.degree. C. and the boiling point of the reaction medium. ##STR1##

  一种制备式（I）化合物的方法，其中R.sub.1和R.sub.2，相同或不同，是氢原子或烷基或烷氧基，或R.sub.1和R.sub.2与它们所连接的碳原子一起形成含有3-6个碳原子的环烷基基团。该方法包括在乙腈或四氢呋喃中，在存在每摩尔式（II）化合物0.002-0.1摩尔的煤载钯的情况下，使用1-2摩尔的三乙胺甲酸盐脱卤化式（lI）的衍生物，其中R.sub.1和R.sub.2的含义与式（1）中相同，Hal是氯或溴原子，并在50℃至反应介质的沸点之间的温度下进行。 ##STR1##
• CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME
  申请人：Zeria Pharmaceutical Co., Ltd.

  公开号：EP1234818A1

  公开（公告）日：2002-08-28

  Provided are calcium salts of a 1,5-benzodiazepine derivative represented by the following formula (I): (wherein, R1 represents a lower alkyl group, R2 represents a phenyl or cyclohexyl group, and Y represents a single bond or a lower alkylene group); a process for preparing the salts; and drugs containing the same as the active ingredient. The compounds exhibit a potent inhibitory activity against the secretion of gastric acid and potent antagonism against gastrin and/or CCK-B receptor.

  本发明提供了由下式(I)代表的1,5-苯并二氮杂卓衍生物的钙盐： (其中，R1 代表低级烷基，R2 代表苯基或环己基，Y 代表单键或低级亚烷基）的 1，5-苯并二氮杂卓衍生物的钙盐；制备这些盐的工艺；以及含有这些盐作为活性成分的药物。 这些化合物对胃酸分泌具有强效抑制活性，对胃泌素和/或 CCK-B 受体具有强效拮抗作用。
• US5719317A
  申请人：——

  公开号：US5719317A

  公开（公告）日：1998-02-17
• US6747022B2
  申请人：——

  公开号：US6747022B2

  公开（公告）日：2004-06-08
• Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same
  申请人：——

  公开号：US20030096809A1

  公开（公告）日：2003-05-22

  Provided are calcium salts of a 1,5-benzodiazepine derivative represented by the following formula (I): 1 (wherein, R 1 represents a lower alkyl group, R 2 represents a phenyl or cyclohexyl group, and Y represents a single bond or a lower alkylene group); a process for preparing the salts; and drugs containing the same as the active ingredient. The compounds exhibit a potent inhibitory activity against the secretion of gastric acid and potent antagonism against gastrin and/or CCK-B receptor.

  提供的是以下公式（I）所代表的1,5-苯二氮䓬啉衍生物的钙盐： （其中，R1代表较低的烷基，R2代表苯基或环己基，Y代表单键或较低的烷基烯基）；一种制备这些盐的方法；以及含有它们作为活性成分的药物。 这些化合物表现出对胃酸分泌的强效抑制活性，以及对胃泌素和/或CCK-B受体的强效拮抗作用。